RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug cocktail aims to shrink tough tumors
Disease control TerminatedThis early-phase trial is testing the safety and best dose of a new oral drug, ZEN003694, when given with standard immunotherapy drugs (nivolumab with or without ipilimumab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Race to control tough ovarian cancer: Three-Way drug showdown
Disease control OngoingThis study is testing which combination of three drugs works best to control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. It involves 444 patients and compares a standard two-drug combo agains…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for tough ovarian cancers: Triple-Drug attack tested
Disease control OngoingThis study is testing whether combining two or three newer drugs works better than standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based drugs. It will involve about 120 women who have alr…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC